Clinical Utility of PGx-Guided Warfarin Dosing Not Proven in Mayo-Medco Study, Reviewer Concludes at Cardiology Meeting | GenomeWeb

By Turna Ray

ATLANTA – The final results of an observational pharmacogenomic-warfarin dosing study led by Medco and the Mayo Clinic do not support the clinical utility of genotyping for heart patients, according to a physician who reviewed the data presented this week at the American College of Cardiology's annual meeting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."